Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play.  | Servier on Friday ...

As AI and automation reshape drug discovery, laboratories themselves are being forced to evolve. Gensler’s Ryley Poblete ...

Almost all of last month’s top 10 pharma TV ad spenders took advantage of February’s two major sporting events to get the word out about their meds. | Almost all of last month’s top 10 pharma TV ad ...

Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

Lonza is at long last shedding its capsules and health ingredients (CHI) business in a private equity sale that could see proceeds of 3 billion Swiss francs ($4 billion) or more.  | Under the deal ...

Forma Life Sciences, which inherited BioDuro’s California production operations earlier this year, has officially ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s domestic drug supply with a 24 billion new Taiwan dollar ($755 million) | ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...